Artesunate/amodiaquine - Drugs for Neglected Diseases Initiative Foundation/Sanofi
Alternative Names: Amodiaquine/artesunate; Artesunate 200mg/amodiaquine 270mg; Artesunate Amodiaquine Winthrop; AS/AQ; ASAQ; ASAQ Winthrop; CoarsucamLatest Information Update: 02 Oct 2021
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; sanofi-aventis
- Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
- Class 3-ring heterocyclic compounds; Aminoquinolines; Antimalarials; Artemisinins; Diethylamines; Herbal medicines; Small molecules; Succinates
- Mechanism of Action Free radical stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malaria
Most Recent Events
- 08 Feb 2019 Chemical structure information added
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malaria(In adolescents, In children, In the elderly, In adults) in France (PO, Tablet)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malaria(In adolescents, In children, In the elderly, In adults) in Mali (PO, Tablet)